Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • TA406
  • Published: 

History

Documents created during the development process.

Expected publication

Final appraisal determination

Draft guidance

Draft scope documents

Invitation to participate